Despite advances in targeted therapies (e.g., BRAF/MEK inhibitors) (24, 25) and immunotherapies (e.g., anti-PD-1/PD-L1/CTLA-4) (26, 27), clinical outcomes remain variable, particularly in metastatic disease, where 5-year survival rates drop below 30%. Here, MAP2K7 is linked to metastatic neoplasm.